Article citationsMore>>

Cimadomo, D., de los Santos, M.J., Griesinger, G., Lainas, G., Le Clef, N., McLernon, D.J., et al. (2023) ESHRE Good Practice Recommendations on Recurrent Implantation Failure. Human Reproduction Open, 2023, hoad023.
https://doi.org/10.1093/hropen/hoad023

has been cited by the following article:

• TITLE: Analysis of the Application Value and Safety of Intrauterine PRP in RIF

  AUTHORS: Anli Liao, Xiaoqiong Luo, Qiuyan Huang

  KEYWORDS: Platelet-Rich Plasma, Assisted Reproductive Technology, Recurrent Implantation Failure, Endometrial Receptivity, Controversy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.1, January 9, 2026

  ABSTRACT: Recurrent Implantation Failure (RIF) affects approximately 10% of in vitro fertilization-embryo transfer (IVF-ET) patients worldwide, posing a significant challenge for reproductive physicians globally. Its etiology is complex and diverse, with maternal factors being paramount, particularly endometrial receptivity (ER). Platelet-rich plasma (PRP), an emerging regenerative medicine therapy, is rich in growth factors and cytokines. Studies have shown that intrauterine PRP infusion can improve endometrial condition and increase embryo implantation rates. This article systematically reviews the application value and safety of intrauterine PRP in RIF patients.